News » Archives » June 2018

Notre Dame licensee Hsiri Therapeutics enters into agreement for the treatment of mycobacterial diseases

Author: Nick Swisher

University of Notre Dame licensee Hsiri Therapeutics, Inc., with its corporate headquarters located in Media, PA, has entered into a license agreement with Shionogi & Co., Ltd. regarding a collaborative licensing, research and development program to discover and develop novel therapeutics for non-tuberculous mycobacterial (NTM) diseases and tuberculosis (TB).

Read More

Notre Dame researchers collaborate in discovery of potential stroke therapy

Author: Deanna Csomo McCool

Mayland Chang and Shahriar Mobashery

A study by researchers at the University of Notre Dame and the University of Missouri at Columbia shows in mice that early administration of a potent compound may increase the window of time in which some stroke patients can receive tPA, a therapeutic that dissolves blood clots.

Read More